Advertisement

Digestive Diseases and Sciences

, Volume 61, Issue 12, pp 3513–3521 | Cite as

Plasma Level of Interleukin-35 as an Independent Prognostic Indicator in Hepatocellular Carcinoma

  • Xiangting Qiu
  • Xinhua Wang
  • Yucui Song
  • Lingling Chen
Original Article

Abstract

Background

Hepatocellular carcinoma is a major type of liver cancer with poor prognosis.

Aim

The aim of the study was to determine the prognostic significance of plasma interleukin-35 level in hepatocellular carcinoma.

Methods

A total of 153 hepatocellular carcinoma patients and 153 healthy controls were enrolled. Blood samples were obtained at admission. Plasma interleukin-35 level was analyzed by enzyme-linked immunosorbent assay. Distribution of T cell subset and expression of Fas/FasL protein were detected by flow cytometry. The patients were followed up for 2 years. Poor prognosis was defined as death of hepatocellular carcinoma.

Results

The plasma levels of interleukin-35 were significantly higher in the patients than the controls (25.1 ± 13.1, 9.3 ± 6.3 pg/mL, P < 0.001). After adjusted for multiple confounding factors, the multivariate logistic regression analyses reported that high level of interleukin-35 (≥25.0 pg/mL) was associated with the poor prognosis in the patients (OR 6.63, 95 % CI 3.27–13.47). Compared with the patients with low level of interleukin-35 (<25.0 pg/mL), the patients with high level of interleukin-35 showed higher frequencies of CD4+CD25+FoxP3+ and CD3+Foxp3+ regulatory T cells (P < 0.001 and P < 0.001) and also showed higher apoptosis levels of CD8+ T cells (P < 0.001).

Conclusion

Circulating interleukin-35 concentration might be an independent prognostic indicator in hepatocellular carcinoma. Such prognostic significance could be partly involved in the activation of regulatory T cell and the apoptosis of CD8+ T cell.

Keywords

Apoptosis Hepatocellular carcinoma Interleukin-35 Prognosis Regulatory T lymphocytes 

Notes

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Grewal P, Viswanathen VA. Liver cancer and alcohol. Clin Liver Dis. 2012;16:839–850.CrossRefPubMedGoogle Scholar
  2. 2.
    Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer. 2015;121:2874–2882.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lai H, Mo X, Yang Y, et al. Association between aflatoxin B1 occupational airway exposure and risk of hepatocellular carcinoma: a case-control study. Tumour Biol. 2014;35:9577–9584.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Chang TS, Wu YC, Tung SY, et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol. 2015;110:836–844.CrossRefPubMedGoogle Scholar
  5. 5.
    White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342–1359.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Inokawa Y, Sugimoto H, Kanda M, et al. Hepatectomy for hepatocellular carcinoma in patients with hemophilia. J Hepatobiliary Pancreat Sci. 2014;21:824–828.CrossRefPubMedGoogle Scholar
  7. 7.
    Singh P, Kaur H, Lerner RG, Patel R, Rafiyath SM, Singh Lamba G. Hepatocellular carcinoma in non-cirrhotic liver without evidence of iron overload in a patient with primary hemochromatosis. Rev J Gastrointest Cancer. 2012;43:36–39.CrossRefGoogle Scholar
  8. 8.
    Cheng WS, Govindarajan S, Redeker AG. Hepatocellular carcinoma in a case of Wilson’s disease. Liver. 1992;12:42–45.CrossRefPubMedGoogle Scholar
  9. 9.
    Fan J, Yang GS, Fu ZR, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai,China. J Cancer Res Clin Oncol. 2009;135:1403–1412.CrossRefPubMedGoogle Scholar
  10. 10.
    Park JG. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. Clin Mol Hepatol. 2015;21:287–294.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Tanabe KK, Curley SA, Dodd GD, Siperstein AE, Goldberg SN. Radiofrequency ablation: the experts weigh in. Cancer. 2004;100:641–650.CrossRefPubMedGoogle Scholar
  12. 12.
    Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer. 2004;40:1474–1484.CrossRefPubMedGoogle Scholar
  13. 13.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMedGoogle Scholar
  14. 14.
    Devergne O, Birkenbach M, Kieff E. Epstein–Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA. 1997;94:12041–12046.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–569.CrossRefPubMedGoogle Scholar
  16. 16.
    Wirtz S, Billmeier U, Mchedlidze T, Blumberg RS, Neurath MF. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology. 2011;141:1875–1886.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol. 2011;186:6661–6666.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Collison LW, Chaturvedi V, Henderson AL, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010;11:1093–1101.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lu Y, Yuan Y. Serum level of interleukin-17 and interleukin-35 as a biomarker for diagnosis of thyroid cancer. J Cancer Res Ther. 2015;11:209–211.CrossRefGoogle Scholar
  20. 20.
    Zhang Y, Sun H, Wu H, Tan Q, Xiang K. Interleukin 35 is an independent prognostic factor and a therapeutic target for nasopharyngeal carcinoma. Contemp Oncol (Pozn). 2015;19:120–124.Google Scholar
  21. 21.
    Zeng JC, Zhang Z, Li TY, et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol. 2013;6:1806–1816.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Gu X, Tian T, Zhang B, et al. Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer. Tumour Biol. 2015;36:2651–2656.CrossRefPubMedGoogle Scholar
  23. 23.
    Fu YP, Yi Y, Cai XY, et al. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer. 2016;114:767–776.CrossRefPubMedGoogle Scholar
  24. 24.
    Ferenci P, Fried M, Labrecque D, et al. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointest Liver Dis. 2010;19:311–317.Google Scholar
  25. 25.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–1474.CrossRefPubMedGoogle Scholar
  26. 26.
    Fu YP, Yi Y, Cai XY, et al. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer. 2016;114:767–776.CrossRefPubMedGoogle Scholar
  27. 27.
    Chen Y, Wang CJ, Lin SH, Zhang M, Li SY, Xu F. Interleukin-35 is upregulated in response to influenza virus infection and secondary bacterial pneumonia. Cytokine. 2016;81:23–27.CrossRefPubMedGoogle Scholar
  28. 28.
    Shibolet O, Alper R, Zlotogarov L, et al. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer. 2003;106:236–243.CrossRefPubMedGoogle Scholar
  29. 29.
    Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132:2328–2339.CrossRefPubMedGoogle Scholar
  30. 30.
    Shi YY, Dai MJ, Wu GP, Zhou PP, Fang Y, Yan XB. Levels of interleukin-35 and its relationship with regulatory T-cells in chronic hepatitis B patients. Viral Immunol. 2015;28:93–100.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Guo CL, Yang XH, Cheng W, et al. Expression of Fas/FasL in CD8+ T and CD3+ Foxp3+ Treg cells–relationship with apoptosis of circulating CD8+ T cells in hepatocellular carcinoma patients. Asian Pac J Cancer Prev. 2014;15:2613–2618.CrossRefPubMedGoogle Scholar
  32. 32.
    Long J, Zhang X, Wen M, et al. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun. 2013;430:364–369.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Xiangting Qiu
    • 1
  • Xinhua Wang
    • 1
  • Yucui Song
    • 1
  • Lingling Chen
    • 1
  1. 1.Department of Clinical LaboratoryYishui Central HospitalYishui County, LinyiChina

Personalised recommendations